Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors

PURPOSE: The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML failing ≥ 2 lines of treatment, partly due to the paucity of head-to-head trials evaluating TKIs. Thus, matching-adjusted i...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Ehab, Mauro, Michael J., Hochhaus, Andreas, Boquimpani, Carla, Minami, Yosuke, Maheshwari, Vikalp Kumar, Saini, Lovneet, Corbin, Regina, Réa, Delphine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356870/
https://www.ncbi.nlm.nih.gov/pubmed/36707445
http://dx.doi.org/10.1007/s00432-022-04562-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356870/
https://www.ncbi.nlm.nih.gov/pubmed/36707445
http://dx.doi.org/10.1007/s00432-022-04562-5

Ejemplares similares